# **Product** Data Sheet

# Lck-IN-2

Cat. No.: HY-163278 CAS No.: 2615173-24-3 Molecular Formula:  $C_{31}H_{32}N_8O_5$ Molecular Weight: 596.64

Target: Src; Apoptosis

Pathway: Protein Tyrosine Kinase/RTK; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description	Lck-IN-2 (compound 12a) is an inhibitor of Lymphocyte-specific protein tyrosine kinase (Lck) with IC <sub>50</sub> of 10.6 nM. Lck-IN-2 reveals efficacy in colon cancer cells with $GI_{50}$ s of 0.24-1.26 $\mu$ M. Lck-IN-2 exhibits an apoptotic effect in Colo201 cells <sup>[1]</sup> .	
IC <sub>50</sub> & Target	Lck 10.6 nM (IC <sub>50</sub> )	
In Vitro	Lck-IN-2 inhibits Lck phosphorylation and induces apoptosis in human colon cancer cells Colo201 in dose-dependent manner <sup>[1]</sup> .  Lck-IN-2 reveals anti-proliferative potencies against various cancer cells, with GI <sub>50</sub> of 0.01-8 $\mu$ M <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.  Western Blot Analysis <sup>[1]</sup>	
	Cell Line:	Colo201
	Concentration:	0-10 μΜ
	Incubation Time:	
	Result:	Reduced the Lck phosphorylation and increased levels of cleaved PARP in dose-dependent manner

## **REFERENCES**

[1]. Hyun Ji S, et al., Identification of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffolds as potent Lck inhibitors as anti-cancer agents. Bioorg Med Chem Lett. 2024 Feb 3:129645.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA